[HTML][HTML] Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li, H Huang - Medicine, 2022 - journals.lww.com
Background: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial.
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li, H Huang - Medicine, 2022 - europepmc.org
Background Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
[HTML][HTML] Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li, H Huang - Medicine, 2022 - ncbi.nlm.nih.gov
Background: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
[HTML][HTML] Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li, H Huang - Medicine, 2022 - journals.lww.com
Background: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
Efficacy and safety of Qinghua Zhixie Decoction against diarrhea-predominate irritable bowel syndrome: A protocol for a randomized controlled trial
L Ji, X Zhao, Y Zhang, P Zhao, R Gong, F Li… - Medicine, 2022 - ingentaconnect.com
Background: Diarrhea-predominant irritable bowel syndrome (D-IBS) is the main subtypes of
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …
irritable bowel syndrome (IBS). In recent years, more than half of IBS patients have received …